The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
Official Title: Phase II Trial of Rituximab Plus Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
Study ID: NCT01611259
Brief Summary: This is an open label, phase II study to evaluate the capacity of Rituximab (Mabthera®) plus Lenalidomide (Revlimid®) to induce objective responses in patients with Mucosa Associated Lymphoid Tissue (MALT) lymphoma presenting with measurable disease.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
AKH Linz, Linz, Oberösterreich, Austria
Klin.Abt.f. Hämatologie; Med.Univ.Graz, Graz, , Austria
Univ.-Klinik f. Innere Medizin V, Innsbruck, , Austria
PMU Salzburg, Salzburg, , Austria
Universitätsklinik f. Innere Medizin I, Vienna, , Austria
Name: Markus Raderer, MD
Affiliation: Allgemeines Krankenhaus der Stadt Wien - Medizinischer Universitätscampus
Role: PRINCIPAL_INVESTIGATOR